Market Snapshot – 21 October 2026
Annovis Bio (ANVS) closed the trading session at 11:32 AM Central Europe with a modest gain of 2.08 %, trading at USD 0.98 per share. The company’s current market capitalisation stands at USD 40.9 million, with a share supply of 42.6 million. In the last 24 hours, roughly USD 689.9 k of ANVS shares changed hands, indicating a moderate level of liquidity.
Despite the recent uptick, Annovis Bio’s equity has fallen 17.65 % since the close of the previous month. The 200‑day simple moving average (SMA) is positioned at USD 2.02, underscoring the stock’s continued struggle to breach its short‑term trend line. The 52‑week high of USD 5.50 was recorded on 28 November 2025, while the 52‑week low of USD 0.95 occurred on 19 October 2026, demonstrating the volatility that has characterised the company’s price action over the past year.
Comparative Performance of Peer Companies
The biopharmaceutical corridor has seen mixed outcomes over the last trading day:
| Ticker | % Change (24 h) | Current Price (USD) | Market Cap (USD mn) | Notable Corporate Events |
|---|---|---|---|---|
| IBIO | +7.89 % | 0.82 | 48.9 | Approved amendments to its 2023 Omnibus Incentive Plan and expanded authorized share capital to 500 million shares in a routine governance exercise. |
| MDAI | –0.66 % | 1.51 | 48.9 | – |
| APLM | –1.76 % | 21.66 | 48.4 | – |
| ACET | –0.22 % | 4.52 | 48.8 | – |
| INKT | +3.14 % | 9.86 | 48.8 | – |
While Annovis Bio edged higher, its peers displayed a broader spectrum of movement, from the significant rise of iBio (IBIO) to the modest decline of Apollomics (APLM). These fluctuations highlight the sector’s sensitivity to both corporate governance actions and broader market sentiment.
Company Profile – Annovis Bio
Annovis Bio, Inc. is headquartered in Berwyn, Pennsylvania, and specialises in the development of therapeutics for neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. The company’s research pipeline also includes orphan indications, notably dementia and Alzheimer’s in Down syndrome. Annovis Bio trades on the New York Stock Exchange and serves customers primarily within the state of Pennsylvania. Further corporate information is available on the company’s website at www.annovisbio.com .
